Topoisomerase	O
I	O
protein	O
expression	O
in	O
primary	B-Cancer
colorectal	I-Cancer
cancer	I-Cancer
and	O
lymph	B-Cancer
node	I-Cancer
metastases	I-Cancer
.	O

Topoisomerase	O
I	O
(	O
topo	O
I	O
)	O
is	O
an	O
important	O
target	O
for	O
the	O
treatment	O
of	O
malignant	B-Cancer
disease	I-Cancer
,	O
especially	O
colorectal	B-Cancer
cancer	I-Cancer
.	O

Because	O
there	O
is	O
little	O
information	O
on	O
the	O
expression	O
of	O
topo	O
I	O
in	O
colorectal	B-Cancer
tumors	I-Cancer
,	O
this	O
study	O
evaluated	O
and	O
characterized	O
topo	O
I	O
protein	O
expression	O
in	O
primary	B-Cancer
colorectal	I-Cancer
cancer	I-Cancer
and	O
lymph	B-Cancer
node	I-Cancer
metastases	I-Cancer
and	O
studied	O
the	O
association	O
between	O
topo	O
I	O
protein	O
expression	O
and	O
clinicopathologic	O
data	O
,	O
p53	O
status	O
,	O
and	O
proliferating	O
cell	O
nuclear	O
antigen	O
(	O
PCNA	O
)	O
status	O
.	O

Immunohistochemistry	O
assay	O
was	O
performed	O
for	O
topo	O
I	O
protein	O
expression	O
in	O
249	O
primary	B-Cancer
human	I-Cancer
colorectal	I-Cancer
cancer	I-Cancer
and	O
42	O
paired	O
lymph	B-Cancer
node	I-Cancer
metastasis	I-Cancer
samples	I-Cancer
.	O

Topo	O
I	O
expression	O
was	O
described	O
as	O
the	O
percentage	O
of	O
cells	B-Cell
staining	O
positive	O
for	O
topo	O
I	O
,	O
along	O
with	O
the	O
intensity	O
and	O
localization	O
of	O
the	O
staining	O
.	O

Clinicopathologic	O
data	O
(	O
sex	O
,	O
age	O
,	O
Dukes	O
'	O
stage	O
,	O
differentiation	O
grade	O
,	O
survival	O
status	O
)	O
,	O
p53	O
status	O
,	O
and	O
PCNA	O
status	O
were	O
statistically	O
analyzed	O
for	O
association	O
with	O
topo	O
I	O
protein	O
expression	O
.	O

Topo	O
I	O
expression	O
in	O
paired	O
primary	B-Cancer
lymph	I-Cancer
node	I-Cancer
metastases	I-Cancer
were	O
studied	O
for	O
concordance	O
.	O

Topo	O
I	O
protein	O
expression	O
was	O
detected	O
in	O
127	O
(	O
51	O
%	O
)	O
samples	B-Cancer
,	O
including	O
24	O
.	O
4	O
%	O
with	O
>	O
50	O
%	O
positive	O
tumor	B-Cell
cells	I-Cell
.	O

The	O
majority	O
had	O
nuclear	B-Cellular_component
(	O
70	O
.	O
1	O
%	O
)	O
or	O
nuclear	B-Cellular_component
and	O
cytoplasmic	B-Organism_substance
staining	O
(	O
17	O
.	O
3	O
%	O
)	O
.	O

A	O
higher	O
percentage	O
of	O
cells	B-Cell
expressing	O
topo	O
I	O
in	O
primary	B-Cancer
colorectal	I-Cancer
cancer	I-Cancer
was	O
significantly	O
associated	O
with	O
advanced	O
age	O
(	O
P	O
=	O
.	O
040	O
)	O
.	O

Patients	O
with	O
rectal	B-Cancer
cancer	I-Cancer
had	O
greater	O
topo	O
I	O
expression	O
than	O
those	O
with	O
colon	B-Cancer
tumors	I-Cancer
(	O
P	O
=	O
.	O
029	O
)	O
.	O

No	O
significant	O
correlation	O
was	O
found	O
between	O
topo	O
I	O
protein	O
expression	O
and	O
sex	O
,	O
Dukes	O
'	O
stage	O
,	O
differentiation	O
grade	O
,	O
survival	O
status	O
,	O
p53	O
status	O
,	O
and	O
PCNA	O
status	O
.	O

Concordance	O
in	O
topo	O
I	O
staining	O
between	O
primary	B-Cancer
and	O
lymph	B-Cancer
node	I-Cancer
metastases	I-Cancer
was	O
observed	O
in	O
33	O
of	O
42	O
cases	O
(	O
P	O
=	O
.	O
029	O
)	O
.	O

This	O
suggests	O
that	O
the	O
activity	O
of	O
topo	O
I	O
inhibitors	O
will	O
not	O
differ	O
across	O
various	O
tumor	B-Cancer
stages	O
,	O
pathology	O
,	O
and	O
patient	O
gender	O
.	O

p53	O
and	O
PCNA	O
status	O
do	O
not	O
appear	O
to	O
influence	O
topo	O
I	O
expression	O
,	O
and	O
topo	O
I	O
has	O
no	O
apparent	O
association	O
with	O
the	O
acquisition	O
of	O
a	O
metastatic	O
phenotype	O
.	O

Topo	O
I	O
expression	O
now	O
needs	O
to	O
be	O
evaluated	O
in	O
patients	O
undergoing	O
topo	O
I	O
-	O
inhibitor	O
therapy	O
,	O
to	O
better	O
define	O
the	O
role	O
of	O
this	O
protein	O
as	O
a	O
predictive	O
marker	O
.	O

